On September 10, 2021 Deciphera Pharmaceuticals, Inc. reported that the Company will host a virtual investor event to review the rebastinib and vimseltinib clinical data to be presented at the upcoming European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2021 on Friday, September 17, 2021, from 10:00 AM to 12:30 PM ET (Press release, Deciphera Pharmaceuticals, SEP 10, 2021, View Source [SID1234587517]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Deciphera’s senior executive team will be joined by the following key opinion leaders at the event:
Dr. Robert L. Coleman, M.D., FACOG, FACS, Gynecologic Oncologist and Chief Scientific Officer at US Oncology Research
William D. Tap, M.D., Chief of the Sarcoma Medical Oncology Service at Memorial Sloan Kettering Cancer Center